Eloxx Pharmaceuticals Announces Publication Demonstrating the Power of its TURBO-ZM™ Platform to Target the Human Ribosome for Therapeutic Benefit

Publication titled “A Novel Class of Ribosome Modulating Agents Exploits Cancer Ribosome Heterogeneity to Selectively Target the CMS2 Subtype of Colorectal…

Related Keywords

Laureen Cassidy ,John Woolford ,Eloxx Pharmaceuticals ,Eloxx Pharmaceuticals Inc ,Nasdaq ,Cancer Research Communications ,Novel Class ,Selectively Target ,Cancer Research ,Ribosome Modulating Agents ,Vijay Modur ,Eukaryotic Ribosome Selective Glycosides ,Private Securities Litigation Reform Act ,Nasdaq Capital Market ,Quarterly Report ,